This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramanathan-Girish, S.
Right arrow Articles by Johnson, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramanathan-Girish, S.
Right arrow Articles by Johnson, K. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2004, p. 4835-4842, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4835-4842.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor

Sandhya Ramanathan-Girish,{dagger} Juliet McColm,{ddagger} John M. Clements,§ Phil Taupin,{ddagger} Sue Barrowcliffe,{ddagger} John Hevizi,{ddagger} Sharon Safrin, Clive Moore,{ddagger} Gary Patou, Heinz Moser, Alison Gadd,{ddagger} Ute Hoch, Vernon Jiang, Denene Lofland, and Kirk W. Johnson*

Genesoft Pharmaceuticals, South San Francisco, California, and British Biotech Pharmaceuticals, Oxford, United Kingdom

Received 27 March 2004/ Returned for modification 26 May 2004/ Accepted 14 August 2004

BB-83698, a potent and selective inhibitor of peptide deformylase, was the first compound of this novel antibacterial class to progress to clinical trials. Single- and/or multiple-dose studies with doses ranging from 10 to 50 mg of BB-83698/kg of body weight were done with mice, rats, and dogs. Intravenous pharmacokinetics were characterized by low to moderate clearances and moderate volumes of distribution for all species. In dogs, but not in rodents, central nervous system (CNS) effects were dose limiting for intravenously administered BB-83698 and were suspected to be related to a high maximum concentration of the agent in plasma (Cmax) rather than to total systemic exposure. Controlled infusion studies with dogs demonstrated that CNS effects could be avoided without compromising systemic exposure by reducing the Cmax. A randomized, double-blind, placebo-controlled, five-way-crossover, single-dose-escalation, phase I study to explore the safety, tolerability, and pharmacokinetics of intravenous BB-83698 at doses ranging from 10 to 475 mg was performed with healthy male volunteers. Systemic exposures were generally in linear relationships with administered doses in animals and humans. Pharmacokinetics were consistent, predictable, and exhibited good allometric scaling among all species (r2 >0.98). Moreover, BB-83698 dosing in humans proceeded to a predicted efficacious exposure (the area under the concentration-time curve/MIC ratio, up to 184) without any clinically significant adverse effects.

* Corresponding author. Mailing address: Genesoft Pharmaceuticals, 7300 Shoreline Ct., South San Francisco, CA 94080. Phone: (650) 837-1864. Fax: (650) 827-0479. E-mail: kirkjohnson{at}comcast.net.

{dagger} Present address: Chiron Corp., Emeryville, Calif.

{ddagger} Present address: Vernalis Ltd., Winnersh, United Kingdom.

§ Present address: Heptagen, Buckingham, United Kingdom.

Present address: Sunesis Pharmaceuticals, South San Francisco, Calif.

Antimicrobial Agents and Chemotherapy, December 2004, p. 4835-4842, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4835-4842.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Teo, J. W. P., Thayalan, P., Beer, D., Yap, A. S. L., Nanjundappa, M., Ngew, X., Duraiswamy, J., Liung, S., Dartois, V., Schreiber, M., Hasan, S., Cynamon, M., Ryder, N. S., Yang, X., Weidmann, B., Bracken, K., Dick, T., Mukherjee, K. (2006). Peptide Deformylase Inhibitors as Potent Antimycobacterial Agents. Antimicrob. Agents Chemother. 50: 3665-3673 [Abstract] [Full Text]  
  • Fieulaine, S., Juillan-Binard, C., Serero, A., Dardel, F., Giglione, C., Meinnel, T., Ferrer, J.-L. (2005). The Crystal Structure of Mitochondrial (Type 1A) Peptide Deformylase Provides Clear Guidelines for the Design of Inhibitors Specific for the Bacterial Forms. J. Biol. Chem. 280: 42315-42324 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»